Q2 FY2026 EarningsQ2 FY26 missed consensus across key earnings metrics: GAAP EPS was -$0.70 vs. -$0.58 expected, and R&D expenses rose to $28.9M, contributing to a wider-than-expected net loss of $40.7M. Revenue remained at zero, in line with consensus for this clinical-stage biotech. The variance was primarily driven by a 148% YoY surge in G&A expenses due to legal costs from the Nippon Shinyaku dispute and pre-commercialization initiatives for Deramiocel.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Capricor Therap(CAPR) the EBIT is -42.95 M (-54.93%), Miss estimate;the EPS is -0.7 (-22.81%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.04B54.93%
-0.03B24.66%
-0.01B30.27%
EPSMiss expectations
-0.722.81%
-0.57560.98%
-0.124421.83%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf